ストックスクリーナーアプリを入手
3.07
2.84%
0.08
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com
Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan
Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et
Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - AD HOC NEWS
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times
Fate Therapeutics lines up four investor conferences in Q3 - Stock Titan
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2500 Index - marketscreener.com
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga
F6T Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - AD HOC NEWS
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView
Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView
Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
Price to sales forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
FATE Forecast — Price Target — Prediction for 2027 - TradingView
Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities - The Globe and Mail
Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
FATE Stock Price, Quote & Chart - ChartMill
Fate Therapeutics Shareholders Back Directors and Governance Plans - The Globe and Mail
Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan
Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director receives 87,900-share stock option grant - Stock Titan
Director at Fate Therapeutics (NASDAQ: FATE) receives 87,900 stock options grant - Stock Titan
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options - Stock Titan
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE) - Stock Titan
[8-K] FATE THERAPEUTICS INC Reports Material Event - Stock Titan
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo - Ad-hoc-news.de
Fate Therapeutics Appoints Laura Hamill To Board Of Directors - TradingView
Fate Therapeutics appoints Laura Hamill to board of directors - Investing.com
Fate Therapeutics appoints Laura Hamill to board of directors By Investing.com - Investing.com South Africa
Fate Therapeutics Appoints Laura Hamill to Board of Directors - The Manila Times
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo Finance
Fate Therapeutics (FATE) Q1 2026 Earnings: EPS Beat on Cost Discipline, Pipeline Progress Drives Stock HigherSegment Revenue Breakdown - newsline.com
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT - Insider Monkey
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
1.53%
3.59%
大文字化:
|
ボリューム (24 時間):